CA3142435A1 - 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors - Google Patents
3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors Download PDFInfo
- Publication number
- CA3142435A1 CA3142435A1 CA3142435A CA3142435A CA3142435A1 CA 3142435 A1 CA3142435 A1 CA 3142435A1 CA 3142435 A CA3142435 A CA 3142435A CA 3142435 A CA3142435 A CA 3142435A CA 3142435 A1 CA3142435 A1 CA 3142435A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- compound
- trifluoromethyl
- pyrrolo
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382475 | 2019-06-06 | ||
| EP19382475.2 | 2019-06-06 | ||
| EP19383221 | 2019-12-31 | ||
| EP19383221.9 | 2019-12-31 | ||
| PCT/EP2020/065658 WO2020245381A1 (en) | 2019-06-06 | 2020-06-05 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3142435A1 true CA3142435A1 (en) | 2020-12-10 |
Family
ID=71083614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3142435A Pending CA3142435A1 (en) | 2019-06-06 | 2020-06-05 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12522598B2 (enExample) |
| EP (2) | EP4789722A2 (enExample) |
| JP (1) | JP7523146B2 (enExample) |
| CN (1) | CN114206868B (enExample) |
| CA (1) | CA3142435A1 (enExample) |
| DK (1) | DK3980416T3 (enExample) |
| FI (1) | FI3980416T3 (enExample) |
| HR (1) | HRP20260656T1 (enExample) |
| LT (1) | LT3980416T (enExample) |
| MX (1) | MX2021014918A (enExample) |
| RS (1) | RS68111B1 (enExample) |
| SI (1) | SI3980416T1 (enExample) |
| WO (1) | WO2020245381A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| MX2020005841A (es) | 2017-12-05 | 2020-09-07 | Oryzon Genomics Sa | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101618B2 (en) | 2005-04-06 | 2012-01-24 | Msd K.K. | 1,4-substituted piperazine derivatives |
| US20100136024A1 (en) | 2008-11-14 | 2010-06-03 | Bartels Stephen P | Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| EP3187497A4 (en) | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10357484B2 (en) | 2015-07-17 | 2019-07-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6970680B2 (ja) | 2016-03-15 | 2021-11-24 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| WO2017222952A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| EP3475275B1 (en) * | 2016-06-23 | 2024-04-10 | Merck Sharp & Dohme LLC | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| WO2018118781A1 (en) | 2016-12-20 | 2018-06-28 | Fmc Corporation | Fungicidal oxadiazoles |
| MX2020005841A (es) | 2017-12-05 | 2020-09-07 | Oryzon Genomics Sa | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. |
-
2020
- 2020-06-05 CN CN202080055779.0A patent/CN114206868B/zh active Active
- 2020-06-05 EP EP26163646.8A patent/EP4789722A2/en active Pending
- 2020-06-05 EP EP20732166.2A patent/EP3980416B1/en active Active
- 2020-06-05 HR HRP20260656TT patent/HRP20260656T1/hr unknown
- 2020-06-05 MX MX2021014918A patent/MX2021014918A/es unknown
- 2020-06-05 WO PCT/EP2020/065658 patent/WO2020245381A1/en not_active Ceased
- 2020-06-05 CA CA3142435A patent/CA3142435A1/en active Pending
- 2020-06-05 FI FIEP20732166.2T patent/FI3980416T3/fi active
- 2020-06-05 SI SI202030773T patent/SI3980416T1/sl unknown
- 2020-06-05 DK DK20732166.2T patent/DK3980416T3/da active
- 2020-06-05 RS RS20260600A patent/RS68111B1/sr unknown
- 2020-06-05 LT LTEPPCT/EP2020/065658T patent/LT3980416T/lt unknown
- 2020-06-05 US US17/596,048 patent/US12522598B2/en active Active
- 2020-06-05 JP JP2021572425A patent/JP7523146B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535290A (ja) | 2022-08-05 |
| SI3980416T1 (sl) | 2026-07-31 |
| HRP20260656T1 (hr) | 2026-07-03 |
| RS68111B1 (sr) | 2026-06-30 |
| LT3980416T (lt) | 2026-06-10 |
| EP3980416B1 (en) | 2026-03-11 |
| DK3980416T3 (da) | 2026-05-26 |
| US20220298156A1 (en) | 2022-09-22 |
| EP3980416A1 (en) | 2022-04-13 |
| FI3980416T3 (fi) | 2026-05-21 |
| JP7523146B2 (ja) | 2024-07-26 |
| WO2020245381A1 (en) | 2020-12-10 |
| US12522598B2 (en) | 2026-01-13 |
| EP4789722A2 (en) | 2026-08-12 |
| CN114206868B (zh) | 2025-02-25 |
| CN114206868A (zh) | 2022-03-18 |
| MX2021014918A (es) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12522598B2 (en) | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as HDAC6 inhibitors | |
| AU2018379321B2 (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| RU2346945C2 (ru) | Производные n-гетероциклилметилбензамидов, их получение и их применение в терапии | |
| JP6522602B2 (ja) | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 | |
| JP6434968B2 (ja) | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 | |
| CA2738026C (en) | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors | |
| US10301306B2 (en) | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | |
| JP7175888B2 (ja) | 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体 | |
| JP2019520396A (ja) | Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素 | |
| JP2019515931A (ja) | イソキノリン−３イル−カルボキサミドならびにその調製および使用の方法 | |
| BR112018013780B1 (pt) | Espiroheptano salicilamidas e compostos relacionados como inibidores de rock, composição farmacêutica e uso dos mesmos | |
| US9676772B2 (en) | Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation method and use thereof | |
| JP2022504703A (ja) | ピリミジン及びピラジンｈｄａｃ１、２阻害剤 | |
| WO2018011227A1 (en) | Inhibitors of tryptophan 2,3-dioxygenase | |
| RU2797613C2 (ru) | Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6 | |
| BR112020010534B1 (pt) | Derivados de 1,2,4-oxadiazol, seus usos como inibidores de histona desacetilase 6 e composição farmacêutica compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240604 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250617 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251017 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260519 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260519 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |